NEWS

NEWARK, CA & SUZHOU, CHINA • MARCH 4, 2022

AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases and rare genetic diseases, announced today that the IND application of company’s lead compound AL01211 was approved by Chinese National Medical Products Administration (NMPA) and Center for Drug Evaluation (CDE). 

NEWARK, CA & SUZHOU, CHINA • DECEMBER 10, 2021

AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that the IND application of company’s lead compound AL01211 was accepted by Chinese National Medical Products Administration (NMPA) and Center for Drug Evaluation (CDE). Dr. Jerry Shen, Chairman, CEO and co-founder of the company said, “this is a big milestone for our young and growing company. AL01211 is a highly specific and potent glucosylceramide synthase inhibitor that is suitable for various non-CNS indications. We are very looking forward to having the clearance and approval from Center for Drug Evaluation (CDE) of NMPA so we can advance to clinical trials in China.”

NEWARK, CA & SUZHOU, CHINA • AUGUST 10, 2021

AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that it has established AceLink Therapeutics China subsidiary at Suzhou Industry Park, China. Dr. Jerry Shen, Chairman, CEO and co-founder of the company said, “we are very excited to have our China company established. This new entity will allow us to interact closely with our local partners, conduct clinical trials in China and recruit local talents to advance our research and development programs. Our mission is to bring products to China market to help Chinese patients with unmet medical needs and to bring the drug candidates developed in China to the global market”. 

NEWARK, CA • JULY 6, 2021

AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for kidney diseases, today announced dosing the first human subject in its Phase I clinical trial evaluating AL01211, a novel small molecule glucosylceramide synthase (GCS) inhibitor.

© Copyright AceLink Therapeutics. All rights reserved